eligibility_summary
Eligibility: Adults with relapsed/refractory B‑cell lymphoma who had initial Relma‑cel, at least one post‑treatment assessment, and are selected for a second infusion, adequate dose available (≈80–150×10^6 CAR‑T), CD19+ residual tumor if feasible, ADA negative, lymphodepletion toxicities ≤Grade 1/baseline, and no unresolved severe AEs from first dose. Exclude: hypersensitivity to components (e.g., DMSO, albumin) or uncontrolled infections.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: Relmacabtagene autoleucel (Relma‑cel, JWCAR029), an autologous, CD19‑directed CAR‑T cell therapy. Mechanism: patient T cells are genetically engineered to express a CAR with 4‑1BB costimulatory and CD3ζ signaling domains, upon binding CD19 they activate, expand, release cytotoxic mediators, and kill target cells. Setting: single‑arm study of a second Relma‑cel infusion in adults with relapsed/refractory large B‑cell lymphoma after suboptimal response to initial Relma‑cel. Cells/pathways targeted: CD19 on malignant B cells, CAR‑T activation via 4‑1BB/CD3ζ signaling, T‑cell effector pathways (perforin/granzyme, cytokine release), leading to apoptosis/clearance of CD19+ lymphoma cells and on‑target B‑cell depletion.